Related Experiment Video

Updated: Aug 17, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet therapy from clinical trials to clinical practice

Shereif H Rezkalla1, Michele Benz

  • 1Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin 54449, USA. rekalla.shereif@marshfieldclinic.org

Clinical Medicine & Research
|June 3, 2005
PubMed

Insights

Antiplatelet therapy, including aspirin and clopidogrel, is crucial for managing acute ischemic syndromes caused by blood clots. Aspirin is recommended for most patients, with clopidogrel offering additional benefits in severe cases.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute ischemic syndromes frequently result from platelet-rich clots at sites of coronary artery disease.
  • Antiplatelet therapy is a fundamental treatment strategy for these conditions.

Purpose of the Study:

  • To outline the current recommendations for antiplatelet therapy in acute ischemic syndromes.
  • To detail the roles of aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors.

Main Methods:

  • Review of current clinical guidelines and evidence for antiplatelet agents.
  • Analysis of therapeutic benefits and indications for aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors.

Main Results:

  • Aspirin (160-325 mg daily) is recommended for nearly all patients.
  • Adding clopidogrel (75 mg daily) to aspirin benefits patients with severe disease for up to one year.
  • Intravenous glycoprotein IIb/IIIa inhibitors are beneficial with coronary intervention, not medical therapy alone.

Conclusions:

  • Aspirin is a foundational antiplatelet agent for acute ischemic syndromes.
  • Combination therapy with aspirin and clopidogrel offers enhanced protection in specific patient groups.
  • The role of glycoprotein IIb/IIIa inhibitors is limited to interventional procedures.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...